On September 19, 2013, Cipher Pharmaceuticals (CPHMF.PK) (DND.TO) announced that U.S. sales and distribution partner for Absorica, Ranbaxy Laboratories (OTC:RBXZF), has received a Paragraph IV Certification Notice of filing from Watson Laboratories, a division of Actavis plc (ACT), of an abbreviated new drug application (NASDAQ:ANDA) for a generic version of Absorica (CIP-isotretinoin capsules). Ranbaxy and Cipher intend to vigorously defend Absorica's intellectual property rights and pursue all available legal and regulatory pathways in defense of the product. But before we get into the details of the filing and how it impacts Cipher's valuation, investors may be curious - What exactly is a Paragraph IV Certification anyway?
A Little Background On ANDA's, Paragraph IV Challenges, and Hatch-Waxman...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|